Exelixis Inc., of South San Francisco, said collaborator Genentech Inc., of South San Francisco, a member of Roche Holding AG, presented preliminary results from a phase Ib trial evaluating the triple combination of cobimetinib, Zelboraf (vemurafenib) and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.